Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Patients with noninfectious uveitis (NIU) are at risk of systemic side effects of long-term glucocorticoid therapy and uncontrolled inflammatory complications. In urgent need to identify more aggressive therapies, adalimumab (ADA) may be the right choice.Objectives: To summarize the curr...

Full description

Bibliographic Details
Main Authors:	Biao Li, Haoran Li, Li Zhang, Yanlin Zheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Pharmacology
Subjects:	adalimumab noninfectious uveitis anti-TNF-α treatment meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.673984/full

Similar Items

The effectiveness of adalimumab treatment for non-infectious uveitis
by: Eiichi Hasegawa, et al.
Published: (2019-04-01)

Profile of adalimumab and its potential in the treatment of uveitis
by: Balevic SJ, et al.
Published: (2016-09-01)

Shaping the Future of Behçet’s Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies
by: Biao Li, et al.
Published: (2023-07-01)

Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan
by: De-Kuang Hwang, et al.
Published: (2018-01-01)

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment
by: Jo L. Dehoorne, et al.
Published: (2023-12-01)

Early administration of adalimumab for paediatric uveitis due to Behçet’s disease
by: Tomona Hiyama, et al.
Published: (2019-06-01)

Biological therapy in treatment of uveitis. Contemporary trends
by: A.V. Zborovskaia, et al.
Published: (2017-10-01)

TNF-α in Uveitis: From Bench to Clinic
by: Qi Jiang, et al.
Published: (2021-11-01)

The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study
by: Hang Song, et al.
Published: (2022-03-01)

Uveitis occurring in a patient with psoriasis during adalimumab therapy: A case report
by: Qiaoli Zheng, et al.
Published: (2022-01-01)

Management of noninfectious posterior uveitis with intravitreal drug therapy
by: Tan HY, et al.
Published: (2016-10-01)

Adalimumab combined with Dexamethasone intravitreal implant in the treatment of refractory noninfectious uveitis macular edema
by: Sui Yuan, et al.
Published: (2024-01-01)

Adalimumab
by: Nilgun Atakan
Published: (2022-04-01)

Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice
by: Maria Esposito, et al.
Published: (2019-07-01)

Adalimumab in Treating Refractory Livedoid Vasculopathy
by: Xiao-Wen Huang, et al.
Published: (2022-04-01)

RESULTS OF RETROSPECTIVE OBSERVATIONAL STUDY OF ADALIMUMAB SAFETY AND EFFICACY IN PATIENTS WITH JUVENILE ARTHRITIS AND UVEITIS
by: Е.I. Alexeeva, et al.
Published: (2011-01-01)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
by: DA Al-Julandani, et al.
Published: (2023-03-01)

Case Report: A Promising Treatment Strategy for Noninfectious Uveitis
by: Xiao-Bao Liu, et al.
Published: (2022-01-01)

Uveitis in Children: The Role of Biological Agents in Its Management
by: Jamel Corredores, et al.
Published: (2023-02-01)

Changes in the basis of vitreous body in case of uveitis treated by adalimumab
by: N.V. Panchenko, et al.
Published: (2015-12-01)

Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study
by: Matthew McHarg, et al.
Published: (2022-01-01)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
by: Weishai Liu, et al.
Published: (2023-05-01)

Successful Treatment of Severe Subcorneal Pustular Dermatosis with Adalimumab
by: Chen J, et al.
Published: (2022-11-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

A Network of Serum Proteins Predict the Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis
by: Jonas J.W. Kuiper, PhD, et al.
Published: (2022-09-01)

Immunosuppressive Medications and COVID-19 Outcomes in Patients with Noninfectious Uveitis in the Era of COVID-19 Vaccinations
by: Samantha J. Sechrist, BS, et al.
Published: (2024-03-01)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
by: Sofia Lanz, et al.
Published: (2021-08-01)

Sarcoidosis-like reaction secondary to adalimumab treatment in a patient with axial spondyloarthritis
by: Diana Alexandra Gonçalves Pimenta, et al.
Published: (2022-07-01)

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
by: Nisha R. Acharya, et al.
Published: (2020-10-01)

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study
by: Hisako Kurozumi-Karube, et al.
Published: (2020-12-01)

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment
by: T.V. Marushko, et al.
Published: (2023-03-01)

Behçet’s Disease Uveitis
by: Morgane Joubert, et al.
Published: (2023-05-01)

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults
by: Hazel Squires, et al.
Published: (2017-11-01)

Serum KL-6 elevation in a uveitis patient with Behçet's disease treated with adalimumab
by: Takashi Ono, et al.
Published: (2020-06-01)

Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
by: Hande Celiker, et al.
Published: (2018-10-01)

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
by: Désirée van der Heijde, et al.
Published: (2018-03-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

Antistreptolysin O Levels in Patients with Non-Infectious Uveitis
by: Esraa Elnagar, et al.
Published: (2023-09-01)

Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
by: Nefyn H. Williams, et al.
Published: (2018-07-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)